Generic drug maker Ranbaxy will pay the state of Tennessee $5.5 million as part of a an agreement to resolve claims the company sold inferior drugs.

The $500 million agreement claims Ranbaxy sold inferior drugs and made false claims about how the drugs were made.

The Justice Department called the settlement the largest in history regarding questionable drug operations by a generic manufacturer.

The whistleblowers complaint alleged Ranbaxy knowingly manufactured, distributed and sold generic pharmaceutical products – whose strength, purity and/or quality fell below the standards required by the FDA.

The products were manufactured between April 2003 and September 2010 in Paonta Sahib and Dewas, India.

Ranbaxy has agreed to pay the states and the federal government $350 million in civil damages and penalties

Tennessee's total share is $5,536,033.17.

Ranbaxy additionally pleaded guilty to seven felony violations of the U.S. Food, Drug, and Cosmetic Act and will pay $150 million in fines.

"We hope this agreement will help improve the safety of drug manufacturing practices throughout the industry," Attorney General Cooper said.